Rifapentine, a synthetic derivate of rifampicin which was developed in 1965, has interesting pharmacological properties, including a long terminal half-life (13 h, compared to 2-3 h for rifampicin) ...and promising bactericidal activity against Mycobacterium tuberculosis. Despite being approved in 1998 by the US Food and Drug Administration (FDA) for the treatment of pulmonary tuberculosis, its global use has been limited by unavailability. In the past decade, new evidence has emerged to define rifapentine as a key component for treatment of active disease and latent infection with M. tuberculosis (LTBI).
BackgroundEuropean-specific policies for tuberculosis (TB) elimination require identification of key populations that benefit from TB screening.AimWe aimed to identify groups of foreign-born ...individuals residing in European countries that benefit most from targeted TB prevention screening.MethodsThe Tuberculosis Network European Trials group collected, by cross-sectional survey, numbers of foreign-born TB patients residing in European Union (EU) countries, Iceland, Norway, Switzerland and the United Kingdom (UK) in 2020 from the 10 highest ranked countries of origin in terms of TB cases in each country of residence. Tuberculosis incidence rates (IRs) in countries of residence were compared with countries of origin.ResultsData on 9,116 foreign-born TB patients in 30 countries of residence were collected. Main countries of origin were Eritrea, India, Pakistan, Morocco, Romania and Somalia. Tuberculosis IRs were highest in patients of Eritrean and Somali origin in Greece and Malta (both > 1,000/100,000) and lowest among Ukrainian patients in Poland (3.6/100,000). They were mainly lower in countries of residence than countries of origin. However, IRs among Eritreans and Somalis in Greece and Malta were five times higher than in Eritrea and Somalia. Similarly, IRs among Eritreans in Germany, the Netherlands and the UK were four times higher than in Eritrea.ConclusionsCountry of origin TB IR is an insufficient indicator when targeting foreign-born populations for active case finding or TB prevention policies in the countries covered here. Elimination strategies should be informed by regularly collected country-specific data to address rapidly changing epidemiology and associated risks.
SETTING: Malta, 2002-2005.OBJECTIVES: To describe the demography and tuberculosis (TB) epidemiology of undocumented immigrants to Malta to tailor TB control strategies to this population.DESIGN: ...Retrospective population study of undocumented immigrants to Malta using national
TB surveillance data.RESULTS: Overall, 85% (4570/5383) of undocumented immigrants were screened on entry using chest X-ray (CXR). Undocumented immigrants were mostly young adults aged 15-34 years (81%) and predominately male (86%), mostly originating from Africa (88%). On screening,
3.5% (160/4570) had CXR suggestive of TB, of whom 12.5% (20/160) had active TB. Using both active and passive surveillance, 33 cases of active TB were diagnosed in these immigrants, 94% of whom were diagnosed during their first 12 months of residence in Malta. Entry screening detected 61%
(20/33) of cases (yield 0.44%). Of the total TB cases in Malta, the proportion of undocumented immigrants increased markedly from 33% in 2002 to 60% in 2005. The reported TB incidence among immigrants was 390/100 000 compared to 2.1/100 000 in the Malta-born.CONCLUSION: Tailoring
TB control strategies to this migrant population is essential for TB control in Malta. Awareness of increased risk of TB needs to be ongoing, not just at entry but for many years after arrival, even in resettlement countries.
